Court Denies Myriad Genetics, Inc.' Motion To Block Rival Ambry Genetics

Ambry Genetics Prevails in Preliminary Injunction Motion Filed by Myriad Genetics

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics (“Ambry”), the worldwide leader in hereditary cancer testing, announced today that it has successfully defended itself against the preliminary injunction motion filed on July 9, 2013 by Myriad Genetics (“Myriad”) and other plaintiffs in University of Utah Research Foundation et al. v. Ambry Genetics Corporation, Case No. 2:13-cv-00640-RJS, pending in the United States District Court for the District of Utah.

Since launching their BRCA product line on the day of the Supreme Court’s ruling against Myriad (June 13, 2013), Ambry has been widely embraced by physicians, genetic counselors and other medical professionals. Given today’s favorable ruling, Ambry will continue to offer all previously launched BRCA-related genetic testing products.

“Today’s win is a victory for the entire genetics community. We’ve all believed for years that products of nature should not be patentable and were thrilled with the Supreme Court ruling in June 2013 affirming this principle. We stood by our convictions after Myriad sued Ambry and are exhilarated by today’s ruling,” said Chief Executive Officer, Charles Dunlop. “Competition stemming from a free market drives all of us to improve and ultimately increases patient access to life-changing information. Our company has been providing innovative genetic testing and excellent service to children’s hospitals and cancer centers for the last 13 years and we are excited to see the industry evolve in this new era.”

Ambry Genetics is represented in the lawsuit by William Gaede and Eric Hagen of McDermott Will & Emery and Edgar Cataxinos of TraskBritt.

About Ambry Genetics®

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory with headquarters in Orange County, California. Since its founding in 1999, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly in sequencing and array services. Ambry has established a reputation for unparalleled service and for over a decade has been at the forefront of applying new technologies to the clinical molecular diagnostics market and to the advancement of disease research. Ambry’s test menu contains multiple BRCA products, including: BRCA1/2 comprehensive analysis (sequencing and deletion/duplication testing), BRCA Ashkenazi Jewish 3-mutation panel and 5 custom multi-gene cancer tests: BRCAplus, BreastNext, OvaNext, PancNext, and CancerNext. To learn more about testing and services available through Ambry, visit www.ambrygen.com.

Contact:
Ambry Genetics
Kimberly Banks
Director of Marketing
949-900-5744
kbanks@ambrygen.com

Help employers find you! Check out all the jobs and post your resume.